Patents by Inventor Hervé Maisonneuve

Hervé Maisonneuve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
    Patent number: 6987103
    Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: January 17, 2006
    Assignee: Stragen Pharma S.A.
    Inventors: Jean-Pierre Robin, François-Xavier Mahon, Hervé Maisonneuve, Frederick Maloisel, Julie Blanchard
  • Treatment of chronic myelogenous leukemia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
    Publication number: 20040019036
    Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising:
    Type: Application
    Filed: March 27, 2003
    Publication date: January 29, 2004
    Inventors: Jean-Pierre Robin, Francois-Xavier Mahon, Herve Maisonneuve, Frederick Maloisel, Julie Blanchard